Vernalis plc is a British based biotech company founded in 2003 by the merger of Vernalis Group with British Biotech in a deal valued at £90 million. The merger allowed British Biotech to ditch its historic but tarnished name.
The company has marketed two drug products; Frovatriptan, to treat migraine, and Apokyn, an apomorphine-based drug for advanced Parkinson's disease.
The company has a development pipeline focused on CNS disease and oncology, and collaborates with pharmaceutical companies including Novartis, Servier, ChemGenex and Serono. It is listed on the London Stock Exchange and is a constituent of the FTSE Fledgling Index.